Brief: Corcept Resubmits New Drug Application For Relacorilant As A Treatment For Patients With Cushing’s Syndrome
17/06/2026 21:29
BRIEF-Corcept Resubmits New Drug Application For Relacorilant As A Treatment For Patients With Cushing’s Syndrome June 17 (Reuters) - Corcept Therapeutics Inc CORT.O:
CORCEPT RESUBMITS NEW DRUG APPLICATION FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH CUSHING’S SYNDROME
CORCEPT THERAPEUTICS - RESUBMISSION INCLUDES ADDITIONAL ANALYSES; EXPECTS SIX-MONTH FDA REVIEW
Source text: ID:nBw77ZWHxa
Further company coverage: CORT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corcept Therapeutics Incorporated
See all newsDrugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case
Live Markets: US earnings forecast jumps further after key reports this week
Live Markets: Who's next for the S&P 500? The clock is ticking
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary